(Circulation. 1997;96:3561-3569.)
© 1997 American Heart Association, Inc.
Articles |
From the Departments of Surgery (Y.J.W., T.J.G.), Medicine (G.P.R., J.L.S., M.E.R.), and Neuroscience (R.J.B.-G.), University of Pennsylvania School of Medicine (Philadelphia). Dr Swain is now at the Department of Medicine, Stanford University Medical Center, S-102, Stanford, CA 94305-5109.
Correspondence to Rita J. Balice-Gordon, PhD, Department of Neuroscience, University of Pennsylvania School of Medicine, 215 Stemmler Hall, Philadelphia, PA 19104-6074. E-mail rbaliceg{at}mail.med.upenn.edu
Background The relationship among the maternal, placental, and uniquely shunted embryonic circulation was explored to provide access to the embryonic cardiovascular system in utero. Manipulation of gene expression in the developing heart would be particularly useful for studying the effects of altered gene expression on cardiac development and in the etiology of congenital cardiac anomalies.
Methods and Results Dye studies demonstrated that intraplacental
injection allows direct access to the embryonic cardiac and systemic
circulation. To evaluate the efficacy of cardiac gene transfer using
this approach, replication-deficient recombinant adenoviral vectors
encoding luciferase or ß-galactosidase as reporter genes were
injected intraplacentally into embryonic day (E)12.5 murine embryos, an
age at which the mass of the heart was observed to be large compared
with other organs. Embryos were assayed for transgene expression at
E15.5 and at birth. Survival rates at these times were similar among
vector-injected and control groups. At E15.5 and at birth, luciferase
activity within the heart was 9- and 23-fold higher, respectively, than
in the remainder of the embryo, although levels of expression were
generally lower at birth than during embryonic life. ß-Galactosidase
expression was observed within all regions of the embryonic heart and
was localized to
15% of atrial and ventricular
cells.
Conclusions Intraplacental delivery of adenovirus at embryonic day 12.5 results in somatic gene transfer to the murine embryonic heart, which persists at least until birth. The combination of intraplacental injection to directly access the fetal coronary circulation and injection at E12.5 when the mass of the heart is large compared with other organs results in transgene expression in cardiac cells. Intraplacental injections early in embryonic life may thus be useful to study the effects of temporal manipulation of gene expression on cardiac development and disease.
Key Words: genes viruses heart defects, congenital cardiovascular diseases
This article has been cited by other articles:
![]() |
G. Christensen, S. Minamisawa, P. J. Gruber, Y. Wang, and K. R. Chien High-Efficiency, Long-Term Cardiac Expression of Foreign Genes in Living Mouse Embryos and Neonates Circulation, January 18, 2000; 101(2): 178 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Lipshutz, R. Sarkar, L. Flebbe-Rehwaldt, H. Kazazian, and K. M. L. Gaensler Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero PNAS, November 9, 1999; 96(23): 13324 - 13329. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Carmeliet, L. Moons, and D. Collen Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis Cardiovasc Res, July 1, 1998; 39(1): 8 - 33. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |